Drug Profile
Zansecimab - Eli Lilly and Company
Alternative Names: LY 3127804Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiopoietin-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID-19 pneumonia; Solid tumours